Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/56812| Title: | An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer. | Monash Health Investigator(s): | Frentzas S. | Monash Health Department(s): | Oncology | Registration Date: | 20-May-2020 | Monash Health Site(s): | Monash Medical Centre | Trial Phase: | Not Applicable | Summary: | The purpose of this study is to examine the safety, anti-cancer activity, and how the body metabolises a new medication called EO1001. Who is it for? You may be eligible for this study if you are aged 18 or over and have metastatic or advanced cancer. Study details All participants in this study will receive the active medication.. All participants will have a single dose of the medication to test how the body metabolises the drug. The drug is taken as an oral tablet, and the dose will depend on when the participant enrols in the study. About a week later, participants will start consuming the medication at the dose they started every day. Treatment will continue from this point, until those running the study decide to halt treatment, or the participant is unable to continue. As part of this study, participants will be required to undergo blood tests to assess safety and undergo scans to determine cancer status. It is hoped this research will demonstrate this medication is safe and effective in treating advanced cancer. | Type: | Clinical trial | Registry ID: | ACTRN12620000583943 | URL: | https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379152 |
| Appears in Collections: | Clinical Trials |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.